MK-677 and Telmisartan Interaction
MK-677 and Telmisartan have a potentially harmful interaction with 64% confidence. Both MK-677 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.
Compound Profiles
MK-677
Ghrelin Receptor Agonist | Oral Growth Hormone Secretagogue
Selectively binds GHS-R1a receptors in hypothalamus and pituitary, triggering pulsatile growth hormone release while maintaining natural circadian patterns..
View full profileTelmisartan
Angiotensin II Receptor Blocker | Cardiac Protection On Cycle
Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take MK-677 with Telmisartan?
Combining MK-677 with Telmisartan is not recommended. Both MK-677 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Is MK-677 and Telmisartan safe together?
This combination carries significant risk. Both MK-677 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.
What are the interactions between MK-677 and Telmisartan?
Both MK-677 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.
How should I time MK-677 and Telmisartan?
MK-677 has a half-life of ~24 hours and Telmisartan has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.